Mundipharma Ranked One of the 2020 Best Workplaces in Europe by Great Place to Work®
11.9.2020 11:36:00 EEST | Business Wire | Press release
Mundipharma is delighted to announce that Great Place to Work® - the global authority on workplace culture – has named it as one of Europe’s Best Workplaces™.
Mundipharma is ranked 12th out of 25 organisations in the Multi-National Company category. Great Place to Work® have recognised a total of 125 organisations across four categories in its newly published Europe’s Best Workplaces™ 2020 list.
Great Place to Work analyzed survey results representing 3,000 organisations and 1.5 million employees across Europe. The survey measured trust and engagement of employees using a series of statements designed to evaluate experience of organizational culture.
This European achievement was made possible after Great Place to Work® presented a number of National ‘Best Workplaces™ awards to Mundipharma companies earlier this year, including Spain, Netherlands, Portugal and Napp.
These European awards follow similar success from across the global Mundipharma network including across the Asia Region. So far this year, Hong Kong, China, Myanmar and Vietnam have all received ‘Best Company’ recognitions from prestigious national awarding bodies.
Speaking about the results, Mundipharma’s Global CEO, Marc Princen, said “Awards like these are testament to our focus on building an inclusive learning culture at Mundipharma where every employee feels appreciated. We believe that people are our most valued asset and if individuals feel accountable, and have the power to make a difference, they can not only deliver for the business but more importantly for the patients we serve.”
The EU list publication has come during the COVID-19 pandemic, which has placed unprecedented pressures upon businesses and employees globally. Organizations on the list are being celebrated for leading the way amid the pandemic, demonstrating care for their employees, their customers and their communities during difficult and exceptional times.
-Ends-
Notes to editors:
About Great Place to Work
Great Place to Work® identifies the top organizations that create great workplaces in the European region through publishing the annual Best Workplaces in Europe list. List determinations are based on thorough analysis of confidential employee feedback through the Trust Index™ survey and a Culture Audit™ examining company practices. The list recognizes companies in four size categories: Small (20-49 employees); Medium (50-499 employees); Large (500+ employees); and Multinational.
To be considered for inclusion, companies must appear on one or more national lists in the region, which includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, The Netherlands, and the United Kingdom.
Multinational organizations must meet the following requirements: 1) Have at least 1,000 employees worldwide, with at least 40% (or 5,000) of those employees based outside the headquarters country; and 2) Appear on at least three national best workplaces lists. Multinationals also receive additional credit for their efforts to successfully create an excellent workplace culture in multiple countries in the region. The data used in the calculation of the regional list comes from national lists published in late 2019 and early 2020.
About the Mundipharma network
Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East.
We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare.
For further information by geographic region please go to www.mundipharma.com (Europe); www.purdue.ca (Canada) and www.mundipharma.com.sg (other ex-US markets).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005140/en/
Contact information
Helen Rae
helenrae@makarahealth.com
T: +44 (0) 7503 652311
Alison Dyson
Alison.Dyson.external@mundipharma.com
T: +44 (0) 7912 887250
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 16:58:00 EET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 15:30:00 EET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 15:22:00 EET | Press release
Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18 th and 19 th11.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a panel on November 19 at 10:30am GMT. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/eyqYNaU4UZTBAgMVip4JTx A live audio webcast of the panel will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/guest_book?session_id=H4EMMyKtX5Gd7TPGHGc3Si A replay of both webcasts will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
